PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration

A large proportion of patients with chronic myeloid leukemia (CML; 20%–50%) develop resistance to imatinib in a BCR-ABL1-independent manner. Therefore, new therapeutic strategies for use in this subset of imatinib-resistant CML patients are urgently needed. In this study, we used a multi-omics appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Rui, Li, Chuting, Wang, Xiuyuan, Li, Zhendong, Wen, Ziqi, Yin, Zhao, Huang, Guiping, Liu, Yanjun, Yang, Juhua, Hu, Haiyan, Nie, Hong, Zhang, Keda, Fei, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208829/
https://www.ncbi.nlm.nih.gov/pubmed/37234746
http://dx.doi.org/10.1016/j.omtn.2023.04.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208829/
https://www.ncbi.nlm.nih.gov/pubmed/37234746
http://dx.doi.org/10.1016/j.omtn.2023.04.026

Ejemplares similares